Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.69980/ejrmwx86

AYURVEDIC MANAGEMENT OF METABOLIC SYNDROME: A CRITICAL REVIEW OF MEDOVAHA SROTAS PATHOLOGY AND INTERVENTION STRATEGIES

Dr Mahendra Kumar Sourtha[1*], Dr. Ramesh Kumar [2]

[1] Senior Medical Officer -1, Govt. Ayurved Hospital, Anokhu, Sikar, Department of Ayurved, Govt. of Rajasthan
[2] Ayurved Medical Officer,Govt Ayurved Hospital, Banthod, Sikar , Department of Ayurved, Govt. of Rajasthan

Corresponding Author- Dr Mahendra Kumar Sourtha
drmsourtha@gmail.com

Abstract
Metabolic Syndrome (MetS) has emerged as a predominant global health crisis, characterized by a complex cluster of risk factors including central obesity, insulin resistance, dyslipidemia, and hypertension. This study provides a comprehensive research paper drafted from the perspective of an advanced researcher in Ayurveda, aimed at correlating the modern biomedical constructs of MetS with the Ayurvedic principles of *Medovaha Srotas* pathology. The investigation explores the anatomical and physiological foundations of *Meda Dhatu* (adipose tissue) and its transport channels, *Medovaha Srotas*, identifying their *Moolasthana* (roots) in the *Vrikka* (kidney) and Vapavahana (omentum) as per classical Samhita descriptions. Through a critical review of *Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya*, the paper delineates the etiology of Santarpanottha Vyadhi (over-nutrition disorders) and the role of *Agni mandya* (metabolic impairment) and Ama (endotoxins) in driving systemic inflammation and insulin resistance. The management strategy integrates *Shodhana* (biopurification) therapies such as *Virechana* and *Udvartana* with *Shamana* (palliative) interventions involving evidence-based herbs like *Guggulu, Haridra* (Curcumin), and *Triphala*. Modern pharmacological pathways, including the modulation of PPAR-gamma, TNF-alpha, and gut microbiota, are synthesized with Ayurvedic concepts to provide a multi-dimensional treatment framework. This research highlights the efficacy of an integrated Ayurvedic approach in managing metabolic biomarkers and reducing the risk of cardiovascular morbidity and type 2 diabetes.[i]

Keywords
Metabolic Syndrome, *Medovaha Srotas*, *Agni mandya*, *Sthaulya* , *Prameha*, *Guggulu*, Curcumin, Insulin Resistance, *Santarpana*, *Virechana* .

1. Introduction

Metabolic syndrome is fundamentally defined as a constellation of metabolic abnormalities that significantly elevate the risk of atherosclerotic cardiovascular diseases and type 2 diabetes mellitus. Historically characterized by the World Health Organization (WHO) and the National Cholesterol

Education Program (NCEP) Adult Treatment Panel III (ATP III), the syndrome represents a global epidemic linked to the transition toward sedentary lifestyles and high-calorie dietary habits. The clinical relevance of the syndrome lies in its multifactorial etiology, involving visceral obesity, a pro-inflammatory state, and systemic insulin resistance. Approximately 20–25% of the world's adult population is estimated to suffer from this condition, resulting in a three-fold increase in the risk of myocardial infarction and stroke.[ii] ,[iii]

In the realm of Ayurveda, this modern medical entity corresponds most closely to the spectrum of *Santarpanottha Vyadhi* diseases arising from over-nutrition and *Medovaha Sroto-dushti* (vitiation of the lipid-carrying channels). The Ayurvedic perspective on human physiology is rooted in the equilibrium of *Dosha* (bio-energies), *Dhatu* (tissues), and *Mala* (waste products), governed by the transformative power of *Agni* (biological fire). The fourth tissue, *Meda Dhatu*, is responsible for snehana (unctuousness) and stability, but its pathological accumulation leads to *Sthaulya* (obesity) and serves as the precursor for Prameha (metabolic urinary disorders, including diabetes).[iv]

The primary challenge in managing Metabolic Syndrome in the twenty-first century is the insufficiency of monotherapy to address its clustered risk factors. While modern medicine often employs separate pharmacological agents for hypertension, dyslipidemia, and hyperglycemia, Ayurveda offers a holistic, multi-targeted approach that aims to restore the systemic *Agni* and clear the Srotas (channels) of metabolic obstructions. This paper critically reviews the pathology of *Medovaha Srotas* and provides evidence-based intervention strategies, integrating classical wisdom with contemporary clinical research.

2. Methodology

This research report is designed as a critical review and synthesis of classical Ayurvedic literature and modern biomedical databases.

1. **Classical Literature Review:** A comprehensive analysis was conducted on the Brihat-Trayi (The Great Triad): the *Charaka Samhita, Sushruta Samhita,* and Ashtanga Hridaya. Specific attention was given to the Sutra Sthana (Fundamental Principles), Vimana Sthana (Measurement/Standardization), and Chikitsa Sthana (Therapeutics). The Chaukhambha edition of these texts was prioritized for consistent shloka indexing and commentary interpretation by Acharyas such as Chakrapanidatta.[v]

2. **Modern Scientific Database Search:** Research snippets and full-text articles were sourced from Scopus and PubMed (2000–2026). The search focused on clinical trials and systematic reviews regarding Metabolic Syndrome, insulin resistance, and Ayurvedic interventions. Key search terms included "Metabolic Syndrome criteria," "insulin resistance pathophysiology," "Curcumin clinical trials," "Guggulu lipid-lowering," and "*Virechana* metabolic efficacy".

3. **Inclusion and Exclusion Criteria:** Only studies following standardized diagnostic criteria for MetS (NCEP ATP III or IDF) were included. Ayurvedic interventions were included if they involved standardized *Shodhana* or *Shamana* protocols as described in classical texts.

4. **Data Synthesis:** The findings were integrated to provide a narrative synthesis that bridges the Ayurvedic concept of *Agni* /Ama with modern theories of inflammation and oxidative stress.

Source Category	Primary Focus	Methodology Application
Classical Samhitas	Anatomical and Physiological roots of *Meda*	Textual analysis of *Medovaha Srotas* Moolasthana.
PubMed/Scopus Trials	Efficacy of Herbal Formulations	Review of randomized controlled trials (RCTs) on Triphala, Haridra, and Guggulu.
Systematic	Global prevalence and	Synthesis of IDF and NCEP ATP III

Reviews	criteria	diagnostic frameworks.
Ayurvedic Case Studies	Clinical Pathogenesis (*Samprapti*)	Analysis of Dhatw*Agni* -mandya and Ama formation.

3. Ayurvedic Review: Physiology of *Meda Dhatu* and *Medovaha Srotas*

3.1. *Meda Dhatu*: Etymology and Function

The term *Meda* is derived from the Sanskrit root *Med-asun*, which means to provide unctuousness or lubrication. In the sequence of tissue transformation (*Dhatu* Parinama), *Meda* is the fourth *Dhatu*, synthesized from the essence of Mamsa *Dhatu* (muscle tissue) through the metabolic action of Medo-dhatw*Agni* .

"मेदोऽस्थिपुष्टिं स्नेहं स्वेदं दृढत्वं च करोति" (*Sushruta Samhita Sutra Sthana 15/5)*

As per Sushruta *Meda Dhatu* provides nourishment to bones, creates unctuousness/lubrication, produces sweat, and provides stability/firmness to the body. *Medo Dhatu* exists in two states: *Baddha Meda* (fixed fat stored in adipose tissues) and *Abaddha Meda* (circulating lipids within the Rasa-Rakta stream). The Abaddha *Meda* is homologous to the modern understanding of serum cholesterol and triglycerides, while *Baddha Meda* correlates with visceral and subcutaneous adipose stores.[vi]

3.2. Anatomical Mapping of *Medovaha Srotas* (Channels of Fat)[vii]

The *Sroto-Vimana* chapter of *Charaka Samhita* defines Srotas as the functional channels of transport and transformation. For Medo *Dhatu*, the specific channels are the *Medovaha Srotas*.

Moolasthana **(Roots of Origin):** Acharyas have provided specific anatomical markers for the roots of these channels, which are highly relevant to modern metabolic screening.

Name of Acharya	**Classical *Moolasthana***	**Modern Anatomical Correlation**
Charaka (Vi. 5/8)	*Vrikka* and *Vapavahana*	Kidneys (Perinephric fat) and Omentum (Visceral fat).
Sushruta (Sha. 9/12)[viii]	*Vrikka* and *Kati*	Kidneys and Lumbosacral region (Waist circumference).
Vagbhata (Ashtanga)[ix]	*Vrikka* and *Mamsa*	Kidneys and Muscle tissue (Intramuscular lipids).

The identification of the *Vapavahana* (omentum) as a root is a profound insight. Modern medical science identifies visceral fat in the omentum as a highly active endocrine tissue that releases free fatty acids into the portal circulation, leading to insulin resistance and hepatic steatosis. Similarly, *Kati* (the waist) is the primary site for measuring abdominal obesity, a prerequisite in the IDF criteria for Metabolic Syndrome[x].

3.3. The Role of *Agni* (Metabolic Fire) in Lipid Balance

Agni is the central regulatory mechanism of all metabolic transformations in Ayurveda. The 13 types of *Agni* (one Jathar*Agni* , five *BhutAgni* , and seven *DhatwAgni*) must remain in a state of equilibrium (*SamAgni*) for health.

In Metabolic Syndrome, the primary pathology is *Agni mandya* (low digestive/metabolic fire), specifically at the levels of *JatharAgni* and *Medo-dhatwAgni* . When *JatharAgni* is impaired, food is not properly digested, leading to the formation of *Ama*—a sticky, toxic byproduct that is undigested and incapable of nourishing subsequent *Dhatu*s.

3.4. Pathophysiology: Modern Vs. Ayurveda

3.4.1. The Modern Paradigm: Insulin Resistance and Inflammation

The hallmark of Metabolic Syndrome is the disruption of insulin signaling and the development of a chronic low-grade inflammatory state.

1. **Visceral Adiposity:** Excess body fat in the abdomen (central obesity) leads to the hypertrophy of adipocytes. These enlarged cells become dysfunctional and secrete high levels of pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and C-reactive protein (CRP).
2. **Insulin Resistance (IR):** IR occurs when insulin-responsive tissues (liver, muscle, and fat) become less sensitive to the hormone. TNF-α further inhibits the insulin receptor signaling pathway in skeletal muscles.
3. **Hepatic Response:** The liver responds by increasing gluconeogenesis and lipid synthesis, leading to high fasting glucose and hypertriglyceridemia.

3.4.2. The Ayurvedic Paradigm: *Sroto-avarodha and Samprapti*

In Ayurveda, the pathophysiology of metabolic disorders is described through the concept of *Santarpanottha Vyadhi* (diseases of over-nutrition) and *Medopradoshaja Vikara*.

"मेदसावृतमार्गत्वात् कोष्ठे धावति मारुतः | सन्धुक्षयति चाप्यग्निमाहारं शोषयत्यपि ||(*Sutra Sthana 21/4-9)*

Acharya Charaka describes the specific pathogenesis of obesity (*Sthaulya*) and its complications in when the channels are obstructed by excess *Meda Dhatu*, the *Vata Dosha* is restricted to the *Koshtha* (abdomen), where it intensifies the *JatharAgni* , leading to rapid digestion and constant hunger).

Steps of *Samprapti* (Pathogenesis):[xi]

1. ***Nidana Sevana*:** Intake of *Guru* (heavy), *Madhura* (sweet), *Snigdha* (oily) foods and sedentary habits.
2. ***Agni* mandya:** Impairment of Jathar*Agni* leads to the formation of *Ama* and *Kleda* (excess moisture/waste).
3. ***Meda* -Vriddhi:** Excessive accumulation of malformed *Meda Dhatu* occurs in the *Medovaha Srotas*.
4. **Sroto-avarodha:** This excess fat blocks the channels of circulation. Other *Dhatu*s (like muscle, bone, and semen) are deprived of nutrition because the circulation is stalled at the level of *Meda*
5. **Vata-Pitta Vitiation:** The blocked Vata causes an abnormal increase in Jathar*Agni* (Tikshn*Agni*), creating a state of "metabolic fire" that consumes everything but creates no healthy tissue, mirroring the "voracious appetite" and high metabolic turnover seen in insulin-resistant patients who fail to achieve satiety.

Comparative Pathophysiology: *Medovaha Srotas* vs. MetS

Modern Biomarker	**Ayurvedic Pathological Component**	**Causal Logic**
Insulin Resistance	*Sroto-avarodha* (Channel Blockage)	Tissues are "blocked" from receiving glucose (nourishment) despite high levels in the stream.
Visceral Obesity	*Abaddha Meda* and *Udara-Kati Vriddhi*	Accumulation of "unbound" fat in the abdomen and roots of *Medovaha Srotas*.
Dyslipidemia	*Bahu-abaddha Meda* and *Kleda*	Excessive, malformed lipid precursors circulating in the Rasa-Rakta *Dhatu*.
Chronic Inflammation	*Ama* and *Dhatu-vitiation*	Metabolic endotoxins triggering systemic responses across all Srotas.
Hypertension	*Vata-vitiation* in channels	Restricted movement of Vata in obstructed vessels, increasing pressure (BP).

4. Clinical Manifestations: Signs and Symptoms

Diagnostic Parameters in Modern Science

According to the NCEP ATP III guidelines, Metabolic Syndrome is diagnosed when three or more of the following conditions are met :

- **Waist Circumference:** >102 cm (men), >88 cm (women).
- **Triglycerides:** ≥150 mg/dL.
- **HDL Cholesterol:** <40 mg/dL (men), <50 mg/dL (women).
- **Blood Pressure:** ≥130/85 mmHg.
- **Fasting Glucose:** ≥100 mg/dL

4.1. Signs and Symptoms in Ayurveda (*Lakshanas*)

Ayurveda describes the symptoms of *Medovaha Sroto-dushti* and *Sthaulya* (obesity) which overlap significantly with the biomarkers of MetS.

Lakshana (Symptom)	Interpretation / Modern Correlation	Reference
Sweda-agaman	Excessive sweating (Hyperhidrosis)	*Su. Sa. Su. 15/14*.
Snigdha-angata	Oily appearance of the body (Seborrhea)	*Su. Sa. Su. 15/14*.
Talu-shosha / Pipasa	Dryness of palate and excessive thirst (Polydipsia)	*Su. Sa. Su. 15/14*.
Sthaulya	Obvious obesity and abdominal girth	*Su. Sa. Su. 15/14*.
Kshudha-adhikya	Excessive hunger (Polyphagia)	*Ca. Sa. Su. 21/4*.
Dourgandhya	Bad body odor	*Ca. Sa. Su. 21/4*.
Gatra-sada	Lethargy or feeling of heaviness	*Santarpanottha Lakshana*.
Javoparodha	Hampered mobility and slow movements	*Ca. Sa. Su. 21/4*.

5. Intervention Strategies: Ayurvedic Management

The management of Metabolic Syndrome (*Medovaha Srotas* disorders) follows a structured protocol: *Nidana Parivarjana* (Elimination of causes), *Shodhana* (Purification), and *Shamana* (Palliative) treatment.

5.1. *Shodhana Chikitsa*: The Radical Purification

Biopurification is essential for clearing *Sroto-avarodha* and restoring the *Agni* .

1. [xii]***Virechana*** **(Therapeutic Purgation):** *Virechana* is the treatment of choice for Pitta-dominant disorders and is highly effective in clearing the *Medovaha Srotas*.
   - **Clinical Evidence:** A randomized controlled trial demonstrated that *Virechana* Karma significantly reduced body weight (from 80.8 kg to 75.1 kg), BMI, and waist circumference in patients with Metabolic Syndrome.
   - **Mechanism:** *Virechana* acts on the liver, improving hepatic metabolism and reducing the levels of inflammatory markers and triglycerides. It has been shown to be safe, with electrolyte levels remaining within normal limits post-procedure.

2. ***Udvartana*** **(Dry Powder Massage):** Massage with dry herbal powders like *Triphala Churna* or *Kulattha Churna* is used to liquefy the subcutaneous fat and open the pores of the sweat glands.
   - **Effect:** Udvartana exhibits catabolic effects on body fat, significantly reducing BMI, waist-hip ratio, and skinfold thickness.

5.2. Shamana Chikitsa: Evidence-Based Herbal Management

1. ***Haridra* (Curcuma longa / Curcumin):**[xiii] Curcumin is a potent phytochemical used in managing hyperglycemia and dyslipidemia.
- **Clinical Insights:** A systematic review of 13 RCTs revealed that curcumin significantly reduces fasting blood sugar (FBS) and diastolic blood pressure. Curcumin acts as a multi-target agent, improving gut microbiota composition and activating PPAR-gamma pathways to enhance insulin sensitivity.
- **Dosage:** 1.2 g of pure curcumin with black pepper (piperine) daily has been shown to promote remission of Metabolic Syndrome symptoms over three months.

2. ***Guggulu* (Commiphora mukul):** Navak Guggulu is the most respected *Lekhana* (scraping) agent in Ayurveda, specifically indicated for *Medoroga* (fat disorders).[xiv]
- **Mechanism:** Guggulsterones act as Farnesoid X Receptor (FXR) antagonists, which significantly improves lipid profiles and reduces the inflammatory markers like CRP and ESR.
- **Clinical Study:** An open-label trial involving Guggulu tablets (500 mg BID) for 24 weeks showed a mean body weight decrease of 4.3 kg and significant metabolic improvements in HbA1c and LDL cholesterol.

3. ***Triphala* (Polyherbal formulation):** Consisting of *Amalaki*, *Bibhitaki*, and *Haritaki*, Triphala is used for its antioxidant and anti-obesity properties[xv].
- **Pharmacology:** Triphala regulates lipid accumulation by downregulating the expression of adipogenic genes like PPAR-gamma and C/EBP-alpha.
- **Clinical Impact:** Meta-analysis of clinical trials shows that oral Triphala leads to a significant decline in body weight (MD = -2.4 kg) and improvements in glycemic control.

4. ***Tryushnadi Churna*:** A randomized double-blind trial confirmed that Tryushnadi Churna, combined with an Ayurvedic diet and yoga, effectively reduces BMI, waist circumference, and body fat percentage in patients with Metabolic Syndrome.[xvi]

5.3. Integrative Explanation: Modern and Ayurveda Perspective

The convergence of modern metabolic science and Ayurveda provides a unique opportunity for personalized medicine.

5.3.1.Adipose Tissue Dysfunction vs. *Medo-dushti*[xvii]

Modern science views the "sick adipocyte" as the root of inflammation. Ayurveda views this as *Medo-vitiation* where the *Dhatu* is "loose" (*Shithila*) and unable to provide stability, becoming instead a reservoir for *Ama*. The "Pendulous" abdomen (*Lambamaana*) described in *Charaka Sutra 21/9* is the physical manifestation of dysfunctional, hypertrophied visceral fat.

5.3.2. Gut Microbiota vs. *Agni*

The recent discovery that gut microbiota dysbiosis contributes to Metabolic Syndrome correlates with the Ayurvedic concept of *MandAgni* and *Ama* formation in the Mahasrotas (gut). Interventions like *Virechana* and herbs like *Triphala* have been proven to modulate gut flora, restoring the microbial balance which Ayurveda traditionally refers to as "restoring *Agni* ".

Pathological Pillar	Modern Scientific Mechanism	Ayurvedic Strategic Counter-measure
Oxidative Stress	ROS generation / Lipid peroxidation	*Rasayana* therapy and antioxidants (*Haridra*, *Triphala*).
Systemic Toxemia	Endotoxemia from gut leakage	*Shodhana* (*Virechana*) and *Ama-pachana*.
Insulin Signaling	Blockade of IRS-1	*Lekhana* (Scraping) drugs to clear channel

	pathway	obstruction.
Lipid Accumulation	Adipocyte hypertrophy	*Udvartana* and *Lekhana Basti* for fat mobilization.

6. Discussion

Metabolic Syndrome is not merely a collection of high numbers on a lab report; it is a fundamental shift in the body's thermodynamic and circulatory efficiency. In Ayurveda, this is expressed through the impairment of *Medovaha Srotas*. The critical review of classical texts confirms that the Moolasthana of these channels—the kidneys and omentum—are exactly the organs most affected by and responsible for metabolic health in the modern clinical paradigm.

The primary pathology involves a "Vicious Circle" of *Agni mandya* and *Sroto-avarodha*. This explains why many patients find it difficult to lose weight or control blood sugar despite calorie restriction; the "blockage" in the channels prevents the utilization of energy, and the vitiated *Agni* continues to produce malformed *Meda* instead of healthy tissues. *Shodhana* therapy, particularly *Virechana* , acts as a "reset button" for the metabolic fire. By eliminating the accumulated *Ama* and Pitta-Kapha wastes, it restores the sensitivity of the tissues to nourishment, which modern science validates as an improvement in insulin sensitivity. The *Shamana* herbs like Haridra (Curcumin) and Guggulu provide sustained support by modulating the molecular targets (NF-kB, PPAR-gamma) that keep the inflammatory cascade active.

A significant insight from this review is the role of *Triphala*. While often considered a simple laxative, the research highlights its role in gene regulation and gut microbiome modulation, making it a "metabolic regulator" rather than just a digestive aid. Integrated lifestyle modifications, including an Ayurvedic diet (avoiding *Navanna* and *Diwaswapna*) and the consistent practice of *Vyayama* (exercise) and *Yoga*, are non-negotiable for long-term remission. This holistic approach addresses the "Santarpanajanya" nature of the syndrome, shifting the individual from a state of over-nutrition/under-utilization to a state of balanced metabolic health.

7. Conclusion

Metabolic Syndrome presents a significant threat to global health, yet its management through the lens of Ayurvedic Kayachikitsa offers a promising, evidence-based alternative to conventional symptomatic treatment. This critical review has established that the pathology of *Medovaha Srotas* accurately encompasses the modern mechanisms of insulin resistance, central obesity, and systemic inflammation.

The integration of *Shodhana* (*Virechana*) for biopurification and *Shamana* (*Haridra, Guggulu, Triphala*) for metabolic regulation provides a comprehensive strategy that targets the root cause *Agni mandya* and *Sroto-avarodha*. Clinical data supports the efficacy of these interventions in reducing weight, BMI, blood glucose, and lipid parameters, thereby mitigating the risk of cardiovascular events.

8. References

1. [i] Shastri, K., & Chaturvedi, G. N. (Eds.). (2012). *Charaka Samhita* (Vidyotini Hindi Commentary). Sutra Sthana, Chapter 21 (Ashtauninditeeya Adhyaya), Shloka 4-9, Page 278-279. Chaukhambha Bharati Academy.
2. [ii] Hauser, S. L., Longo, D. L., & Jameson, J. L. (Eds.). (2022). *Harrison's Principles of Internal Medicine* (21st ed.). McGraw Hill Education. https://doi.org/10.1036/0071802150
3. [iii] 19. GBD 2015 Obesity Collaborators. (2017). Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *New England Journal of Medicine*, 377, 13-27. https://doi.org/10.1056/NEJMoa1614362

4. [iv] Shastri, K., & Chaturvedi, G. N. (Eds.). (2012). *Charaka Samhita* (Vidyotini Hindi Commentary). Vimana Sthana, Chapter 5 (Sroto Vimana), Shloka 8, Page 510. Chaukhambha Bharati Academy.
5. [v] Shastri, K., & Chaturvedi, G. N. (Eds.). (2012). *Charaka Samhita* (Vidyotini Hindi Commentary). Sutra Sthana, Chapter 23 (Santarpaniya Adhyaya), Shloka 3-8, Page 295. Chaukhambha Bharati Academy.
6. [vi] Shastri, A. D. (Ed.). (2024). *Sushruta Samhita* (Ayurved-Tattva-Sandeepika Hindi Commentary). Sutra Sthana, Chapter 15, Shloka 5, Page 68. Chaukhambha Sanskrit Sansthan.
7. [vii] Sharma, H., & Chandola, H. M. (2011). Ayurvedic concept of obesity, metabolic syndrome, and diabetes mellitus. *The Journal of Alternative and Complementary Medicine*, 17(6), 549-552. https://doi.org/10.1089/acm.2010.0690
8. [viii] Shastri, A. D. (Ed.). (2024). *Sushruta Samhita* (Ayurved-Tattva-Sandeepika Hindi Commentary). Sutra Sthana, Chapter 9 (Dosha*Dhatu*mala kshayavruddhi Vijnaniya Adhyaya), Shloka 12, Page 67. Chaukhambha Sanskrit Sansthan.
9. [ix] Tripathi, B. (Ed.). (2014). *Ashtanga Hridayam* (Nirmala Hindi Commentary). Sutra Sthana, Chapter 11 (Dosha-adi-vijnaniya Adhyaya), Shloka 1-17, Page 113. Chaukhambha Sanskrit Sansthan.
10. [x] Patel, H., & Tank, N. (2026). Decoding the Yakrut-*Meda* s Axis: MASLD in the Framework of Medovaha Sroto-Dushti. *International Journal of Ayurveda and Pharma Research*, 13(12), 129-135. https://doi.org/10.47070/ijapr.v13i12.3912
11. [xi] Garasia, J. S., & Goyal, M. (2021). Effect of Triphala Kajjali tablet for the management of metabolic syndrome: a single case study. *International Journal of Advances in Medicine*, 8(12), 1876-1880. https://doi.org/10.18203/2349-3933.ijam20214528
12. [xii] Chaturvedi, A., Nath, G., Yadav, V. B., & Singh, J. P. (2020). A clinical study on *Virechana* Karma (therapeutic purgation) over gut microbiota in obesity. *Journal of Ayurveda and Integrative Medicine*, 11(4), 405-411. https://doi.org/10.1016/j.jaim.2020.06.002
13. [xiii] Tabrizi, R., et al. (2023). The effects of curcumin supplement on metabolic indices in patients with metabolic syndrome: A systematic review and meta-analysis. *Frontiers in Endocrinology*, 14, 1216708. https://doi.org/10.3389/fendo.2023.1216708
14. [xiv] Fadnavis, K. K., Rathi, R. B., et al. (2025). Evaluation of the Comparative Efficacy of Navak Guggulu in the Management of *Sthaulya* : A Randomized Controlled Trial. *JMIR Research Protocols*, 14, e58838. https://doi.org/10.2196/58838
15. [xv] Bairwa, V. K., Kashyap, A. K., Meena, P., & Jain, B. P. (2025). Triphala's characteristics and potential therapeutic uses in modern health. *International Journal of Physiology, Pathophysiology and Pharmacology*, 17(2), 19-36. https://doi.org/10.62347/OBSS5026
16. [xvi] Shukla, S., et al. (2024). Efficacy of tryushnadi churna in metabolic syndrome with obesity: A randomized double blind controlled clinical trial. *Journal of Ayurveda and Integrative Medicine*, 15(4), 100973. https://doi.org/10.1016/j.jaim.2024.100973
17. [xvii] Deliwala, K., & Deole, Y. S. (2025). Ayurvedic perspective of mitochondrial dysfunction and vitiation of *Meda Dhatu* in obesity (*Sthaulya*). *Journal of Drug Research in Ayurvedic Sciences*, 10(Suppl 2), S144-S150. https://doi.org/10.4103/jdras.jdras_10_25